HUDDINGE, Sweden--(BUSINESS WIRE)--Regulatory News:
(STO:MVIR-B)
Financial summary for the second quarter
-- Net turnover totalled SEK 564.0 million (SEK 40.7 m), of which SEK 500.7 million was contributed by royalties for simeprevir. Revenues from Medivir’s own pharmaceutical sales totalled SEK 62.9 million, SEK 21.7 million of which derived from sales of Olysio and SEK 41.2 million from sales of other pharmaceuticals. The profit/loss after tax was SEK 327.8 million (SEK -63.7 m).
Help employers find you! Check out all the jobs and post your resume.
